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Hyperglycemia is common in critically ill patients and is associated with increased 
morbidity, mortality, rate of infections and length of hospital stay. For decades, 
hyperglycemia in critically ill population was considered an adaptive response and 
interventions were only considered if diabetic ketoacidosis (DKA) or severe hyperos-
molar states developed. Furnary et al published studies showing lower sternal wound 
infection rates in cardiac surgical patients with control of glucose (180-220 mg/dl). This 
led to the dissemination of the “Portland Protocol,” but it was not widely accepted.1, 2
Management of hyperglycemia changed with the publication of Van Den Berghe 
study.3 This was a prospective, randomized, controlled study involving adults admitted 
to a surgical intensive care unit (ICU) who were receiving mechanical ventilation (MV). 
A total of 1548 patients were enrolled with patients randomly assigned to two groups. 
One group received intensive insulin therapy (IIT) with goal blood glucose of 80-110 
mg/dl. The second group received conventional treatment whereby insulin was given 
only if the blood glucose level exceeded 215 mg/dl with goal glucose level of 180-200 
mg/dl.
The primary outcome measure was death from any cause during intensive care. The 
main secondary outcome measures were in-hospital death; the number of days in the 
intensive care unit and the need for prolonged intensive care (more than 14 days) or 
readmission; the need for ventilatory support, renal replacement therapy, or inotropic 
or vasopressor support. At 12 months, IIT reduced mortality during intensive care from 
8.0% with conventional treatment to 4.6% (P<0.04) in intensive treatment group. The 
benefit of intensive insulin therapy was attributable to its effect on mortality among 
patients who remained in the intensive care unit for more than five days (20.2% with 
conventional treatment, as compared with 10.6% with IIT; P=0.005). The greatest 
reduction in mortality involved deaths due to multiple-organ failure with a proven 
septic focus. IIT also reduced overall in-hospital mortality by 34%.
Subsequently, in another single center study,4 Van Den Berghe randomly assigned 1200 
patients in medical ICU to strict normalization of blood glucose levels (80-110 mg/dl) 
with the use of insulin infusion or to conventional therapy. The study showed no signifi-
cant difference in hospital mortality (40.0% in the conventional-treatment group vs. 
37.3% in the intensive-treatment group, p=0.33). However, IIT reduced morbidity and 
mortality in patients that stayed in ICU for three or more days. The reasons for reduced 
morbidity in patients who received IIT were the prevention of acquired kidney injury, 
earlier weaning from MV, and earlier discharge from the medical ICU and hospital.
A number of multicenter studies were performed following the initial Van Den Berghe 
trial in an attempt to replicate the earlier results. VISEP (Volume Substitution and 
Insulin Therapy in Severe Sepsis) study5 and Glucocontrol study6 were prospective, 
multicenter randomized control trials whereas Wiener study7 was a meta-analysis of 
29 randomized controlled trials having a total of 8432 patients. The results of these 
studies showed no significant difference in mortality in the conventional and tight 
control groups but increased episodes of severe hypoglycemia.
Given the conflicting data regarding 
tight glycemic control, the NICE-SUGAR 
study 8 was undertaken. This was a multi-
center randomized control trial which 
enrolled 6104 patients. Study compared 
intensive target glucose of 80 to 108 mg/
dl to the conventional target of 180 mg/
dl or less. 
Primary outcome was death from any 
cause within 90 days after randomiza-
tion. Secondary outcomes were survival 
in first 90 days, cause-specific death, 
duration of MV, length of stay in the ICU, 
and total length of stay in the hospital. 
The intervention was discontinued when 
patients were discharged from ICU or 
eating and were resumed if the patient 
was readmitted within 90 days. Blood 
glucose <40 mg/dl was considered a 
serious adverse event. One-third of the 
patients were surgical patients and two-
thirds were medical patients. Mortality 
in intensive target group was 27.5% 
compared to 24.9% in conventional 
group (p=0.02). The incidence of severe 
hypoglycemia (<40 mg/dl) was 6.8% in 
intensive group compared with 0.5% in 
conventional group (p<0.001).
There were a number of differences 
between Van Den Berghe trial and NICE-
SUGAR trial, which may help explain their 
divergent results. Van Den Berghe study 
was performed at a single center and 
considered reduction of glucose level 
only if it was markedly elevated (>215 
mg/dl). In contrast, NICE-SUGAR study 
was multinational and the glucose level 
in conventional group was targeted at 
only a mildly elevated range of 144 to 
180 mg/dl. Most patients in Van Den 
Berghe trial received parenteral nutrition 
whereas enteral nutrition was the rule in 
NICE-SUGAR study.
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The strengths of NICE trial include its 
large, multicenter patient population, 
vigorous statistical analysis and broad 
representative spectrum of critically 
ill patients. However, some of the 
downfalls were open-label study design 
and premature discontinuation of treat-
ment in 10% of the patients. Increased 
risk of death from IIT in NICE-SUGAR 
study can be attributed to multiple 
factors including direct harmful effects 
of insulin and neuroglycopenia that 
warrants further studies.9
An summary, IIT seems to save lives in the 
initial Van Der Berghe trial but its results 
are yet to be replicated, particularly in 
any multicenter trial. Critical care and 
endocrinologic societies have backed 
away from recommending intensive 
insulin therapy. ADA/AACE Inpatient Task 
Force recommends that insulin infusion 
should be used to control hypergly-
cemia with the starting threshold of 
180 mg/dl. Once IV insulin is started, 
the target glucose is between 140 
and 180 mg/dl. Lower glucose targets 
(110-140 mg/dl) may be appropriate in 
selected patients. Targets <110 mg/dl are 
not recommended.10 
HYPERGLYCEMIA IN  
BRAIN INJURED PATIENTS 
Hyperglycemia is a common secondary 
insult in traumatic brain injury (TBI), 
subarachnoid hemorrhage (SAH), and 
acute ischemic stroke and has been 
consistently associated with poor neuro-
logical outcome.11 
ISCHEMIC STROKE 
Several studies have evaluated the effect 
of IIT in acute ischemic stroke patients 
with hyperglycemia.12,13 UK Glucose 
Insulin in Stroke Trial was the largest 
randomized clinical trial, which enrolled 
933 patients and showed no clinical 
benefit of IIT.14 
INSULINFARCT trial randomized 180 
patients with acute stroke to receive 
IIT or subcutaneous insulin treatment 
during the first 24 h.15 It demonstrated 
that IIT in the first 24 h was associated 
with larger infarct growth and was not 
recommended.
 
Mortality
Study IIT (%) Conventional (%) p value
Van Den Berghe (2001) 4.6 8 <0.04
Van Den Berghe (2006) 37.3 40 0.33
VISEP (2008) (At 28 days) 24.7 26 0.74
Glucocontrol (2009) (At 28 days) 18.7 15.3 0.14
NICE-SUGAR (2009) 27.5 24.9 0.02
Hypoglycemia
Study IIT (%) Conventional (%) p value
VISEP (2008) 17 4.1 <0.001
NICE-SUGAR (2009) 6.8 0.5 <0.001
Glucocontrol (2009) 8.7 2.7 <0.0001
Sample Size
Study n  (Total) n   (Conventional) n   (IIT)
Van Den Berghe (2001) 1548 783 765
Van Den Berghe (2006) 1200 605 595
VISEP (2008) 537 290 247
Glucocontrol (2009) 1101 551 550
NICE-SUGAR 6104 3050 3054
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Meanwhile, the incidence of hypogly-
cemic events was markedly increased 
among patients treated with IIT.23 This 
was confirmed in an additional random-
ized trial with total of 523 patients 
including 94 TBI patients. IIT was not 
associated with improved survival and 
was associated with increased occur-
rence of hypoglycemia.24 
Current clinical trials do not show any 
benefit of tight glucose control with IIT 
in TBI patients with increased episodes 
of hypoglycemia.25 
CONCLUSION
In summary, significant body of litera-
ture has shown that hyperglycemia is 
common in patients with TBI, SAH, and 
ischemic stroke and that it is related to 
poor outcome. However, no concrete 
evidence exists that tight glycemic 
control improves outcome in these 
patients. It might on the contrary lead 
to hypoglycemic episode with delete-
rious effects on the injured brain due to 
secondary neuronal injury.
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AHA/ASA recommends that it is reason-
able to treat hyperglycemia to achieve 
blood glucose levels in a range of 140 
to 180 mg/dl and to closely monitor to 
prevent hypoglycemia in patients with 
acute ischemic stroke16 (Class II a; Level 
of Evidence C).
SUBARACHNOID  
HEMORRHAGE
Hyperglycemia may have detrimental 
effects in patients with subarachnoid 
hemorrahge by increasing chances of 
infection, cerebral ischemia and by facili-
tating the progression from ischemia to 
irreversible infarction.
The majority of the studies using IIT 
reported episodes of hypoglycemia. 
Insulin therapy inducing episodes of 
low glucose was associated with cere-
bral infarction, vasospasm, and worse 
functional outcome 3 months following 
SAH.17  There is only one randomized trial 
where 40 patients receive IIT. This study 
showed no significant improvement in 
clinical outcome or the incidence of 
vasospasm.18
Currently there is no evidence that 
hyperglycemia in SAH patients should be 
treated with IIT. This treatment is accom-
panied by an increase in hypoglycemic 
episodes.
AHA/ASA recommends that glucose 
management with strict avoidance of 
hypoglycemia may be considered as 
part of the general critical care manage-
ment of patients with Aneurysmal 
SAH19 (Class IIb; Level of Evidence B). 
TRAUMATIC BRAIN INJURY
Hyperglycemia contributes to poor 
outcome in TBI patients. Hyperglycemia 
has been shown to worsen ischemic 
brain injury in experimental studies with 
animals. One study analyzing cortical 
contusion injury in rats found that 
hyperglycemia worsens the injury with 
superimposed ischemia.20 In two class III 
human studies, hyperglycemia has been 
associated with worsened outcome.21,22 
A randomized controlled trial of 97 
patients with severe TBI compared 
a regimen of IIT versus conventional 
management. No significant differ-
ences were observed in mortality and 
poor functional outcome at 6 months. 
3
Shoukat, MD et al.: Managing Hyperglycemia in Critically Ill Patients
Published by Jefferson Digital Commons,
23JHN JOURNAL 
Managing Hyperglycemia
20. Cherian L., Goodman JC, Robertson CS. 
Hyperglycemia increases brain injury caused 
by secondary ischemia after cortical impact 
injury in rats. Crit Care Med 1997; 25: 1378-
1383.
21. Lam AM, Winn HR, Cullen BF, et al. 
Hyperglycemia and neurological outcome 
in patients with head injury. J Neurosurg 
1991;75:545-551.
22. Young B, Ott L, Dempsey R, et al. Relationship 
between admission hyperglycemia and 
neurologic outcome of severely brain-injured 
patients. Ann Surg 1989;210:466-473.
23. Bilotta F, Caramia R, Cernak I, Paoloni FP, 
Doronzio A, Cuzzone V, et al. Intensive insulin 
therapy after severe traumatic brain injury: 
a randomized clinical trial. Neurocrit Care 
(2008) 9:159–66.doi:10.1007/s12028-008-
9084-9
24. Arabi YM, Dabbagh OC, Tamim HM, et al. 
Intensive versus conventional insulin therapy: 
a randomized controlled trial in medical and 
surgical critically ill patients. Crit Care Med. 
2008 Dec; 36(12): 3190-7.
25. Marion DW. Optimum serum glucose levels 
for patients with severe traumatic brain injury. 
F1000 Med Rep. 2009 May 28; 1.
Fridays,	7:00	am
De Palma Auditorium
1025	Walnut	Street 
College	Building,	Basement 
Philadelphia,	PA	19107
Neurosurgery
  Grand Rounds
Overall Goals & Objectives
•  Evaluate current controversies in 
neurosurgery
•  Discuss routine occurrences in 
neurosurgical practice and evaluate them 
in terms of outcome and alternative 
methods of management
•  Review recent advances and current 
therapeutic options in the treatment of  
various neurosurgical disorders.
Sidney Kimmel Medical College of Thomas 
Jefferson University is accredited by the 
ACCME to provide continuing medical 
education for physicians.
Sidney Kimmel Medical College designates 
this educational activity for a maximum  
of 1 AMA PRA Category 1 Credit(s)(TM). 
Physicians should only claim credit  
commensurate with the extent of their 
participation in the activity. 
For additional information and a schedule 
of speakers, please contact: 
Janice Longo, 215-503-7008 
janice.longo@jefferson.edu 
4
JHN Journal, Vol. 11 [], Iss. 1, Art. 3
http://jdc.jefferson.edu/jhnj/vol11/iss1/3
